* TuHURA Biosciences Inc is expected to report resultson November 11 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for TuHURA Biosciences Inc is for a loss of 10 cents per share.
* The one available analyst rating on the shares is "buy".
* The average consensus recommendation for the biotechnology & medical research peer group is also "Buy".
* Wall Street's median 12-month price target for TuHURA Biosciences Inc is $15.00, above its last closing price of $5.27.
This summary was machine generated November 8 at 15:48 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。